Neoplasm Metastasis
Conditions
Keywords
Maximum Tolerated Dose, Solid Tumors, Locally Advanced Tumors, Metastatic Solid Tumors, Relapsed or refractory, BRAFV600 or RAS-mutated solid tumors, Melanoma, Colorectal Carcinomas Papillary, Thyroid carcinomas, Pancreatic ductal Adenocarcinomas, Non -small cell lung cancer [NSCLC]
Brief summary
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
Detailed description
CC-90003-ST -001 is an open-label, multicenter, Phase 1a study in subjects with locally-advanced or metastatic, solid tumors who are intolerant of, resistant to, or have relapsed after at least one line of therapy and for whom no standard therapy exists. The study will be conducted in two parts: Dose Escalation (Part 1) and Cohort Expansion (Part 2). Subjects may continue CC-90003 until progression of their underlying malignancy, the occurrence of intolerable toxicity, or physician/subject decision to discontinue CC-90003. In Part 1, cohorts of subjects with relapsed or refractory solid tumors will receive increasing doses of CC-90003 in order to assess its safety and tolerability, the maximum tolerated dose (MTD), and PK profile. In Part 2, cohorts of subjects with specific tumors that harbor mutations involving the Mitogen -Activated Protein Kinase (MAPK) pathway will receive CC-90003 at or below the MTD until progression of disease, intolerable toxicity, or physician/subject decision to discontinue CC-90003.
Interventions
DRUGCC-90003
CC-90003 PO once daily
Sponsors
Celgene
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Eligible study subjects in Part 1 and Part 2 must be 18 years or older 2. Eligible study subjects must have histologic or cytologic confirmation of advanced, unresectable or metastatic solid tumors, and have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 3. Eligible study subjects must have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 4. Eligible study subjects must exhibit acceptable liver, bone marrow, renal and cardiac functions as assessed by laboratory tests, ECG and ECHO or MUGA scan.
Exclusion criteria
1. Subjects with symptomatic or unstable CNS metastases 2. Subjects with a history of recent (within 28 days) systemic therapy for their underlying malignancy 3. Subjects who have had surgery/radiotherapy within 2 weeks prior to start of study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Accumulation index of CC-90003 | Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | Accumulation represents the relationship between the dosing interval and the rate of elimination for the drug |
| PK-Area under the plasma concentration time curve (AUC) | Cycle 1, Day 1, 2, 3, (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | Area under the plasma concentration -time curve of CC-90003 |
| PK-Time to maximal plasma concentration (Tmax) | Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | The time to reach Cmax |
| PK- terminal half-life; t1/2 | Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15, 16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | Terminal phase elimination half-life (t1/2) is calculated as follows: t1/2 =ln(2)/λz, where λz is the first order rate constant associated with the terminal portion of the CC-90003 plasma concentration curve |
| PK-Apparent total body clearance (CL/F) | Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose) 15, 16, , Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | The apparent total body clearance of CC-90003 from plasma |
| PK- Apparent Total Volume of Distribution (Vz/F) | Cycle 1, Day 1, 2, 3 (predose) 8, 11 (predose), 15,16, Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | PK- Apparent Total Volume of Distribution (Vz/F) During the terminal phase for CC- 90003 |
| Summary of the adverse events (type, severity, and incidence) related to CC- | Up to 36 months | An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values regardless of etiology. |
| Dose Limiting Toxicities of CC-90003 | Up to 18 months | Number of participants with dose limiting toxicities during the Dose Escalation Phase |
| Maximum Tolerated Dose (MTD) of CC-90003 | Up to 36 months | The MTD is defined as the highest dose level at which no more than 1 in 6 participants experiences a dose- limiting toxicity (DLT) during the first 28 day cycle of treatment |
| Pharmacokinetics (PK) observed maximum concentration (Cmax) | Cycle 1, Day 1, 2, 3 (predose), 8, 11 (predose), 15, 16, , Cycle 2, Day 1, Cycle 3, Day 1 and at discontinuation | The maximally observed plasma concentration of CC-90003 (Cmax) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | Up to 36 months | Duration of response is the time from the start of study treatment until the first documentation of an objective response (either CR or PR). |
| Disease Control | Up to 36 Months | The proportion of subjects who achieve a best response of SD (documented at least 56 days after the start of study treatment) PR, or CR |
| Progression Free Survival | Up to 36 months | PFS is defined as the time from the start of study treatment until progression (PD) or patient death (any cause), whichever occurs first |
| Overall Survival | Up to 36 months | Overall survival is defined as the time from start of study treatment until the date of death from any cause. |
| Response Rate based on RECIST 1.1 | Up to 36 months | The proportion of subjects who achieve a best response of CR or PR. |
Countries
Australia, United States
Outcome results
None listed